Skip to main content

Table 2 Patient characteristics of patients still in OST at end of study at the different OST units

From: Linkage to hepatitis C treatment in two opioid substitution treatment units in Gothenburg, Sweden: a retrospective cohort study

 

Patients still on OST 2018/12/31 (n = 181)

Hospital-based unit (n = 89)

Downtown unit n = 92

Baseline

End of study

p valued

Baseline

End of study

p valued

Baseline

End of study

p valued

Sex (M/F)

173/8

-

-

86/3

-

-

87/5

 

-

Age (Years, mean (SD))

45.5 (9.7)

-

-

44.6 (9.5)

-

-

46.4 (9.8)

-

-

Treatmenta (buprenorphine/methadone/suboxone)

-

142/35/4

 

-

70/17/2

-

-

72/18/2

-

anti-HCVb ( ±)

103/76

103/77

n.s

50/37

50/38

n.s

53/39

53/39

n.s

HCV RNA/Ag ( ±)

67/36

46/58

0.003

31/19

18/32

0.009

36/17

28/26

n.s

Patients attending Clinic of Infectious Diseasesc (yes/no)

35/32

31/15

n.s

21/10

12/6

n.s

14/22

19/9

0.009

Time to last HCV-test, years (median, IQR)

1.2 (0.3–4.0)

1.3 (0.6–1.8)

0.002

5.0 (1.0–5.0)

1.3 (0.3–1.7)

 < 0.0001

0.6 (0.3–1.7)

1.3 (0.7–1.8)

n.s

  1. SD Standard deviation, HCV Hepatitis C virus, Ag Antigen, IQR Interquartile range, n.s. Not significant
  2. aTreatment data only assessed at End of study
  3. bMissing data for two patients at baseline and for one patient at end of study
  4. cPatients who had attended a visit at the Clinic of Infectious diseases during the past year or a had new appointment scheduled the following year
  5. dTime to last HCV-test—Wilcoxon signed-rank test, all other comparisons—Chi-square test